NEW YORK - IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies with a current market capitalization of $23.42 million, has announced encouraging Phase ...
INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results